F-box and leucine rich repeat protein 19Genealiases: CXXC11 · Fbl19 · JHDM1C
Q-omics provides the consensus-scored FBXL19 profile across patient tissues and cancer cell-line models. FBXL19 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, FBXL19 is differentially expressed in 16, with the highest sampling consensus in KIRP. Additionally, FBXL19 RNA expression shows 19,154 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight MESO, KIRP, and ACC as cancer lineages where FBXL19 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXL19 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXL19 survival associations across molecular data types. FBXL19 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXL19 RNA expression–survival associations across cancer types. High FBXL19 expression shows unfavorable associations in MESO, KIRC, LIHC, ACC, UVM and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for FBXL19 RNA expression.
This table summarizes FBXL19 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FBXL19. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXL19 shows higher tumor expression in KIRP, HNSC, COAD, KIRC, LIHC and LUAD. The KIRP box plot shows higher FBXL19 RNA expression in tumor versus normal tissue (log2 FC = +1.520, t-test p < 0.001).
This table shows molecular features associated with FBXL19 in patient tissues and cancer cell lines. In patient samples, FBXL19 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXL19 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
